Current Scientific Considerations to Verify Physiologically-Based Pharmacokinetic Models and Their Implications for Locally Acting Products.
作者信息
Zhao Liang, Seo Paul, Lionberger Robert
机构信息
Division of Quantitative Methods and Modeling, Office of Research and Standards, Office of Generic Drugs, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
Division of Biopharmaceutics, Office of New Drug Products, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, US Food and Drug Administration, Silver Spring, Maryland, USA.
出版信息
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):347-351. doi: 10.1002/psp4.12421.
Abstract
摘要
相似文献
1
Current Scientific Considerations to Verify Physiologically-Based Pharmacokinetic Models and Their Implications for Locally Acting Products.验证基于生理的药代动力学模型的当前科学考量及其对局部作用产品的影响。
CPT Pharmacometrics Syst Pharmacol. 2019 Jun;8(6):347-351. doi: 10.1002/psp4.12421.
2
Physiologically Based Pharmacokinetic Modeling in Regulatory Science: An Update From the U.S. Food and Drug Administration's Office of Clinical Pharmacology.生理药代动力学建模在监管科学中的应用：美国食品和药物管理局临床药理学办公室的最新进展。
J Pharm Sci. 2019 Jan;108(1):21-25. doi: 10.1016/j.xphs.2018.10.033. Epub 2018 Oct 29.
3
Clinical Applications of Physiologically Based Pharmacokinetic Modeling: Perspectives on the Advantages and Challenges.基于生理的药代动力学建模的临床应用：优势与挑战的视角
Ther Drug Monit. 2020 Feb;42(1):157-158. doi: 10.1097/FTD.0000000000000714.
4
Regulatory experience with physiologically based pharmacokinetic modeling for pediatric drug trials.用于儿科药物试验的基于生理学的药代动力学建模的监管经验。
Clin Pharmacol Ther. 2012 May;91(5):926-31. doi: 10.1038/clpt.2012.19.
5
Physiologically Based Pharmacokinetic Model Qualification and Reporting Procedures for Regulatory Submissions: A Consortium Perspective.基于生理学的药代动力学模型在监管提交中的资格认证和报告程序：联合观点。
Clin Pharmacol Ther. 2018 Jul;104(1):88-110. doi: 10.1002/cpt.1013. Epub 2018 Feb 2.
6
Best practice in the use of physiologically based pharmacokinetic modeling and simulation to address clinical pharmacology regulatory questions.生理药代动力学建模和模拟在解决临床药理学监管问题方面的最佳实践。
Clin Pharmacol Ther. 2012 Jul;92(1):17-20. doi: 10.1038/clpt.2012.68.
7
The Application of Physiologically Based Pharmacokinetic Modeling to Predict the Role of Drug Transporters: Scientific and Regulatory Perspectives.基于生理的药代动力学模型在预测药物转运体作用中的应用：科学与监管视角
J Clin Pharmacol. 2016 Jul;56 Suppl 7:S122-31. doi: 10.1002/jcph.740.
8
Impact of physiologically based pharmacokinetic models on regulatory reviews and product labels: Frequent utilization in the field of oncology.基于生理的药代动力学模型对监管审评和产品标签的影响：在肿瘤学领域的频繁应用。
Clin Pharmacol Ther. 2017 May;101(5):597-602. doi: 10.1002/cpt.622. Epub 2017 Mar 15.
9
Physiologically based pharmacokinetic modeling: from regulatory science to regulatory policy.基于生理学的药代动力学建模：从监管科学到监管政策。
Clin Pharmacol Ther. 2014 May;95(5):478-80. doi: 10.1038/clpt.2014.46.
10
Applications of physiologically based pharmacokinetic (PBPK) modeling and simulation during regulatory review.在监管审查期间，生理基于药代动力学（PBPK）建模和模拟的应用。
Clin Pharmacol Ther. 2011 Feb;89(2):259-67. doi: 10.1038/clpt.2010.298. Epub 2010 Dec 29.
引用本文的文献
1
Clinical Ocular Exposure Extrapolation for a Complex Ophthalmic Suspension Using Physiologically Based Pharmacokinetic Modeling and Simulation.使用基于生理药代动力学建模与模拟对复杂眼科混悬剂进行临床眼部暴露外推
Pharmaceutics. 2024 Jul 9;16(7):914. doi: 10.3390/pharmaceutics16070914.
2
Update on the advances and challenges in bioequivalence testing methods for complex topical generic products.复杂局部用仿制药生物等效性测试方法的进展与挑战综述
Front Pharmacol. 2024 Feb 8;15:1330712. doi: 10.3389/fphar.2024.1330712. eCollection 2024.
3
Physiologically Based Biopharmaceutics Model (PBBM) of Minimally Absorbed Locally Acting Drugs in the Gastrointestinal Tract-Case Study: Tenapanor.胃肠道中局部作用的微量吸收药物的基于生理的生物药剂学模型（PBBM）——案例研究：替那帕诺
Pharmaceutics. 2023 Dec 4;15(12):2726. doi: 10.3390/pharmaceutics15122726.
4
Applications of Modeling and Simulation Approaches in Support of Drug Product Development of Oral Dosage Forms and Locally Acting Drug Products: a Symposium Summary.建模与仿真方法在支持口服剂型和局部作用药物产品药物开发中的应用：研讨会总结。
AAPS J. 2023 Oct 2;25(6):96. doi: 10.1208/s12248-023-00862-x.
5
Mechanistic modeling of drug products applied to the skin: A workshop summary report.药物经皮制剂的机制建模：研讨会总结报告。
CPT Pharmacometrics Syst Pharmacol. 2023 May;12(5):575-584. doi: 10.1002/psp4.12893. Epub 2022 Dec 1.
6
Clinical Ocular Exposure Extrapolation for Ophthalmic Solutions Using PBPK Modeling and Simulation.临床眼部暴露外推法在眼科溶液中的应用：基于 PBPK 建模与模拟。
Pharm Res. 2023 Feb;40(2):431-447. doi: 10.1007/s11095-022-03390-z. Epub 2022 Sep 23.
7
Predicting Regional Respiratory Tissue and Systemic Concentrations of Orally Inhaled Drugs through a Novel PBPK Model.通过新型 PBPK 模型预测口服吸入药物的区域性呼吸组织和全身浓度。
Drug Metab Dispos. 2022 May;50(5):519-528. doi: 10.1124/dmd.121.000789. Epub 2022 Mar 4.
8
Development of PBPK model for intra-articular injection in human: methotrexate solution and rheumatoid arthritis case study.建立人关节内注射的 PBPK 模型：甲氨蝶呤溶液和类风湿关节炎病例研究。
J Pharmacokinet Pharmacodyn. 2021 Dec;48(6):909-922. doi: 10.1007/s10928-021-09781-w. Epub 2021 Sep 26.
9
Physiologically-based pharmacokinetic modeling to support bioequivalence and approval of generic products: A case for diclofenac sodium topical gel, 1.基于生理学的药代动力学模型支持仿制药的生物等效性和批准：以双氯芬酸钠凝胶 1 为例
CPT Pharmacometrics Syst Pharmacol. 2021 May;10(5):399-411. doi: 10.1002/psp4.12600. Epub 2021 Mar 9.
10
In Vitro Dissolution and in Silico Modeling Shortcuts in Bioequivalence Testing.生物等效性测试中的体外溶出和计算机模拟捷径
Pharmaceutics. 2020 Jan 4;12(1):45. doi: 10.3390/pharmaceutics12010045.
本文引用的文献
1
Generating Model Integrated Evidence for Generic Drug Development and Assessment.生成用于仿制药开发和评估的模型综合证据。
Clin Pharmacol Ther. 2019 Feb;105(2):338-349. doi: 10.1002/cpt.1282. Epub 2019 Jan 20.
2
Regulatory framework on bioequivalence criteria for locally acting gastrointestinal drugs: the case for oral modified release mesalamine formulations.局部作用胃肠道药物生物等效性标准的监管框架：口服改性释放美沙拉嗪制剂的情况。
Expert Rev Clin Pharmacol. 2017 Sep;10(9):1007-1019. doi: 10.1080/17512433.2017.1348227. Epub 2017 Jul 6.
3
Mechanistic Oral Absorption Modeling and Simulation for Formulation Development and Bioequivalence Evaluation: Report of an FDA Public Workshop.用于制剂开发和生物等效性评估的机制性口服吸收建模与模拟：美国食品药品监督管理局公开研讨会报告
CPT Pharmacometrics Syst Pharmacol. 2017 Aug;6(8):492-495. doi: 10.1002/psp4.12204. Epub 2017 Jul 11.
4
Measurement of in vivo Gastrointestinal Release and Dissolution of Three Locally Acting Mesalamine Formulations in Regions of the Human Gastrointestinal Tract.三种局部作用美沙拉嗪制剂在人体胃肠道区域的体内胃肠道释放和溶解测定
Mol Pharm. 2017 Feb 6;14(2):345-358. doi: 10.1021/acs.molpharmaceut.6b00641. Epub 2016 Dec 23.
5
Open Flow Microperfusion as a Dermal Pharmacokinetic Approach to Evaluate Topical Bioequivalence.开放流微灌注作为一种评估局部生物等效性的皮肤药代动力学方法。
Clin Pharmacokinet. 2017 Jan;56(1):91-98. doi: 10.1007/s40262-016-0442-z.
6
Validating Whole-Airway CFD Predictions of DPI Aerosol Deposition at Multiple Flow Rates.验证多流速下 DPI 气溶胶沉积的全气道 CFD 预测。
J Aerosol Med Pulm Drug Deliv. 2016 Dec;29(6):461-481. doi: 10.1089/jamp.2015.1281. Epub 2016 Apr 15.
7
Application of Physiologically Based Pharmacokinetic (PBPK) Modeling to Support Dose Selection: Report of an FDA Public Workshop on PBPK.基于生理的药代动力学（PBPK）模型在支持剂量选择中的应用：美国食品药品监督管理局（FDA）关于PBPK的公开研讨会报告
CPT Pharmacometrics Syst Pharmacol. 2015 Apr;4(4):226-30. doi: 10.1002/psp4.33. Epub 2015 Apr 17.
Zotero 插件